Diabeloop has developed an algorithm that is hosted on a dedicated handset and serves as a bridge between continuous glucose monitors and insulin pumps. Every five minutes, the handset receives a glucose reading via Bluetooth and the algorithm analyzes the readings alongside information about the patient’s physiology, history, meals and exercise to determine the insulin dose to administer.
In a 12-week trial, Diabeloop found that patients with Type 1 diabetes who used its Diabeloop Generation 1 (DBLG1) with the Cellnovo insulin patch-pump and Dexcom G5 CGM found that time in range improved by 17.6 percentage points over one year of real-world use, leading Diabeloop to report that about half of the group that used its device achieved recommended outcomes, versus 27% under standard treatment. On average, patients using the system spent less than 20 minutes a day in hypoglycemia, compared to the maximum of 60 minutes recommended in guidelines.
To read more, CLICK HERE.
